Northern Trust Corp Boosts Position in Stryker Co. (NYSE:SYK)

Northern Trust Corp raised its position in Stryker Co. (NYSE:SYK - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,606,237 shares of the medical technology company's stock after acquiring an additional 420,153 shares during the quarter. Northern Trust Corp owned approximately 0.95% of Stryker worth $1,298,426,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Chicago Capital LLC boosted its holdings in shares of Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares during the last quarter. Zhang Financial LLC boosted its stake in shares of Stryker by 55.0% during the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after acquiring an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA grew its position in shares of Stryker by 5.0% during the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after acquiring an additional 1,400 shares during the period. Metis Global Partners LLC increased its stake in shares of Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after purchasing an additional 1,561 shares in the last quarter. Finally, US Bancorp DE increased its stake in shares of Stryker by 0.5% in the 4th quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock worth $65,829,000 after purchasing an additional 976 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Price Performance

Shares of SYK stock traded up $3.14 on Wednesday, reaching $374.06. The company's stock had a trading volume of 2,251,733 shares, compared to its average volume of 1,353,911. The company has a market capitalization of $142.77 billion, a price-to-earnings ratio of 48.20, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The stock's fifty day simple moving average is $366.89 and its 200-day simple moving average is $373.50. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm posted $3.46 EPS. Analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Analysts Set New Price Targets

Several analysts have issued reports on the company. BTIG Research set a $403.00 price target on Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research note on Wednesday, January 29th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price target on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Finally, Stifel Nicolaus raised their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Stryker has a consensus rating of "Moderate Buy" and an average target price of $423.53.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.